Daratumumab for the treatment of refractory ANCA-associated vasculitis

Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options. One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostendorf, Lennard, Burns, Marie, Wagner, Dimitrios Laurin, Enghard, Philipp, Amann, Kerstin, Mei, Henrik, Eckardt, Kai-Uwe, Seelow, Evelyn, Schreiber, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Vasculitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835944/
https://www.ncbi.nlm.nih.gov/pubmed/36627149
http://dx.doi.org/10.1136/rmdopen-2022-002742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835944/
https://www.ncbi.nlm.nih.gov/pubmed/36627149
http://dx.doi.org/10.1136/rmdopen-2022-002742

Ejemplares similares